Skip to Content
주식/증권 ➡️ 중립

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

요약

The next six months may be decisive for the biotech.